Published in Recent Prog Horm Res on January 01, 2004
Dynamically reshaping signaling networks to program cell fate via genetic controllers. Science (2013) 2.26
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist (2013) 1.35
Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis (2010) 1.17
Stable isotope labeling by amino acids in cell culture (SILAC) and quantitative comparison of the membrane proteomes of self-renewing and differentiating human embryonic stem cells. Mol Cell Proteomics (2009) 1.17
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One (2009) 1.05
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol (2011) 1.05
Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One (2012) 1.04
Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. PLoS One (2012) 1.00
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol (2012) 1.00
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol (2009) 0.98
Tyrosine phosphorylation of nuclear-membrane protein emerin by Src, Abl and other kinases. J Cell Sci (2009) 0.97
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. Toxicol Appl Pharmacol (2008) 0.95
ErbB signaling in cardiac development and disease. Semin Cell Dev Biol (2010) 0.95
Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol (2015) 0.94
Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol (2009) 0.91
Neurotrophins induce neuregulin release through protein kinase Cdelta activation. J Biol Chem (2009) 0.90
Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clin Res Cardiol (2012) 0.89
Proteomic characterization of HIV-modulated membrane receptors, kinases and signaling proteins involved in novel angiogenic pathways. J Transl Med (2009) 0.85
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res (2010) 0.85
Muscle development, regeneration and laminopathies: how lamins or lamina-associated proteins can contribute to muscle development, regeneration and disease. Cell Mol Life Sci (2012) 0.83
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol (2015) 0.83
ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol (2015) 0.83
Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One (2013) 0.82
The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts (2013) 0.82
Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol (2014) 0.81
Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health (2010) 0.80
Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. Br J Cancer (2012) 0.80
Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure. J Geriatr Cardiol (2012) 0.79
The functional diversity of essential genes required for mammalian cardiac development. Genesis (2014) 0.79
When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells (2014) 0.78
The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. Exp Clin Cardiol (2009) 0.78
The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failure. BMC Genomics (2014) 0.78
Neuregulin 1-Beta cytoprotective role in AML 12 mouse hepatocytes exposed to pentachlorophenol. Int J Environ Res Public Health (2006) 0.78
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. Cells (2014) 0.77
The role of heat shock proteins and co-chaperones in heart failure. Philos Trans R Soc Lond B Biol Sci (2018) 0.76
Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. J Appl Genet (2013) 0.76
Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. Oncoimmunology (2016) 0.76
Erbb2 is required for cardiac atrial electrical activity during development. PLoS One (2014) 0.76
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol (2016) 0.75
Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel) (2016) 0.75
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes. Clin Transl Med (2017) 0.75
Cardiotoxicity associated with targeted cancer therapies. Mol Clin Oncol (2016) 0.75
Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Pract (2017) 0.75
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol (2014) 0.75
Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics (2017) 0.75
Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium. Gene (2017) 0.75
Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism. Neuron (2005) 2.46
Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci U S A (2003) 2.44
Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci (2005) 2.21
Neural crest stem cells undergo multilineage differentiation in developing peripheral nerves to generate endoneurial fibroblasts in addition to Schwann cells. Development (2004) 1.98
p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron (2008) 1.97
The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology (2008) 1.79
Cholinergic input is required during embryonic development to mediate proper assembly of spinal locomotor circuits. Neuron (2005) 1.77
Genetically encoding unnatural amino acids for cellular and neuronal studies. Nat Neurosci (2007) 1.76
Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology (2003) 1.76
Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. J Neurosci (2003) 1.75
Adeno-associated virus effectively mediates conditional gene modification in the brain. Proc Natl Acad Sci U S A (2002) 1.72
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci U S A (2007) 1.57
Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology (2003) 1.34
ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci U S A (2004) 1.29
The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci U S A (2004) 1.22
A disorganized innervation of the inner ear persists in the absence of ErbB2. Brain Res (2006) 1.21
Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci (2002) 1.19
Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci (2007) 1.17
Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet (2002) 1.13
Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron (2003) 1.12
A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci U S A (2005) 1.08
Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci U S A (2006) 1.08
Loss of the oxidative stress sensor NPGPx compromises GRP78 chaperone activity and induces systemic disease. Mol Cell (2012) 1.06
Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci U S A (2002) 1.03
The bound leading the bound: target-derived receptors act as guidance cues. Neuron (2002) 1.01
Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J Neurosci (2006) 0.99
erbB2 is required for G protein-coupled receptor signaling in the heart. Proc Natl Acad Sci U S A (2006) 0.95
Acetylcholine negatively regulates development of the neuromuscular junction through distinct cellular mechanisms. Proc Natl Acad Sci U S A (2010) 0.95
Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol (2008) 0.94
Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res (2002) 0.93
Nestin negatively regulates postsynaptic differentiation of the neuromuscular synapse. Nat Neurosci (2011) 0.89
p75 reduces beta-amyloid-induced sympathetic innervation deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2009) 0.83
The role of corticotropin-releasing factor receptors in stress and anxiety. Integr Comp Biol (2002) 0.83
Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine (2002) 0.82
Gene targeting reveals multiple essential functions of the neuregulin signaling system during development of the neuroendocrine and nervous systems. Ann N Y Acad Sci (2002) 0.77
Catecholamine biosynthesis and secretion: physiological and pharmacological effects of secretin. Cell Tissue Res (2011) 0.76
P45 forms a complex with FADD and promotes neuronal cell survival following spinal cord injury. PLoS One (2013) 0.76
Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity. Endocrinology (2010) 0.76
ZASC1 knockout mice exhibit an early bone marrow-specific defect in murine leukemia virus replication. Virol J (2013) 0.75
Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest (2017) 0.75
Activation of corticotropin releasing factor receptor type 2 in the heart by corticotropin releasing factor offers cytoprotection against ischemic injury via PKA and PKC dependent signaling. Regul Pept (2011) 0.75
Wylie Vale: neuroendocrine master. Proc Natl Acad Sci U S A (2012) 0.75